

Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)

A. Blauvelt,¹ K.C. Duffin,² N. Magnolo,³ J. Weisman,⁴ M. Stähle,⁵ D. Wilsmann-Theis,⁶ M. Wang,⁷ K. Wixted,⁷ B. Szilagyi,⁸ L. Puig⁹

Presented at the 42nd Annual Fall Clinical Dermatology Conference | Las Vegas, NV | October 20–23, 2022

Objective

To evaluate early clinical and health-related quality of life (HRQoL) responses at Week 4 in patients with moderate to severe plaque psoriasis treated with bimekizumab (BKZ), adalimumab (ADA), ustekinumab (UST), and secukinumab (SEC) in four phase 3/3b trials.

Introduction

- Speed of response is an important treatment consideration for patients with plaque psoriasis;¹ 90% of patients in a recent cross-sectional survey ranked rapid response as high importance, with an average expectation of complete skin clearance within 4 weeks.²
- Improvement in HRQoL is also an important treatment goal, given that psoriasis is a chronic disease and can place a significant burden on patients' lives.^{3,4}

Materials and Methods

- Data are reported in parallel from BE SURE, BE VIVID, BE RADIANT, and BE READY for patients who received BKZ 320 mg every 4 weeks (Q4W) or active comparators (Figure 1).⁵⁻⁸
- We report the proportion of patients achieving a $\geq 75\%$ improvement from baseline in Psoriasis Area and Severity Index (PASI 75), PASI 90, PASI 100, and Dermatology Life Quality Index (DLQI) 0/1 at Week 4 in each trial.
- Missing data were accounted for using non-responder imputation (NRI).

Results

- These analyses include 478 patients from BE SURE (319 BKZ; 159 ADA), 484 patients from BE VIVID (321 BKZ; 163 UST), 743 patients from BE RADIANT (373 BKZ; 370 SEC), and 349 patients from BE READY (349 BKZ); baseline characteristics of these patients have been reported previously.⁵⁻⁸
- At Week 4, PASI 75, PASI 90, and PASI 100 were achieved by a greater proportion of BKZ-randomized patients vs active comparators (Figure 2).
- Furthermore, a greater proportion of patients randomized to BKZ vs active comparators achieved DLQI 0/1 at Week 4 (Figure 2).


Summary

Data are reported in parallel from the initial 4-week treatment period of BE SURE, BE VIVID, BE RADIANT, and BE READY

Bimekizumab vs Adalimumab, Ustekinumab, Secukinumab


At Week 4:
Greater skin clearance with bimekizumab; including higher rates of PASI 100
Health-related quality of life benefit with bimekizumab; as measured by DLQI 0/1

Figure 1 Study design: Included patients



BE VIVID and BE READY included placebo arms which were not included in these analyses. ^aAll patients randomized to bimekizumab received 320 mg Q4W; ^bAll patients randomized to adalimumab in BE SURE received 80 mg at baseline, 40 mg at Week 1, then Q2W; ^cPatients in BE VIVID received ustekinumab at baseline, Week 4, then Q12W. Ustekinumab dosing was based on patient weight at baseline: patients weighing ≤ 100 kg received one ustekinumab 45 mg injection and one placebo injection, patients >100 kg received two ustekinumab 45 mg injections; ^dAll patients randomized to secukinumab in BE RADIANT received 300 mg weekly to Week 4, then Q4W.

Figure 2 Week 4 PASI 75, PASI 90, PASI 100, and DLQI 0/1 responses in BE SURE, BE VIVID, BE RADIANT, and BE READY (NRI)



p values for the comparison of treatment groups were based on the Cochran-Mantel-Haenszel test from the general association. In BE SURE, BE VIVID, and BE RADIANT, comparisons between BKZ and active comparators at Week 4 for PASI 90, PASI 100, and DLQI 0/1 were not pre-specified and therefore were not controlled for multiplicity; the corresponding p values are nominal for all trials. Comparisons for PASI 75 response at Week 4 were pre-specified and were controlled for multiplicity in all trials. [†]p<0.001 vs active comparator; [†]nominal p<0.001 vs active comparator; [†]nominal p=0.010 vs active comparator.

ADA: adalimumab; BKZ: bimekizumab; BSA: body surface area; DLQI: Dermatology Life Quality Index; HRQoL: health-related quality of life; PASI 75/90/100: $\geq 75\%/90\%/100\%$ improvement from baseline in Psoriasis Area and Severity Index; Q2W: every 2 weeks; Q4W: every 4 weeks; Q12W: every 12 weeks; SEC: secukinumab; UST: ustekinumab.

Institutions: ¹Oregon Medical Research Center, Portland, Oregon, USA; ²Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; ³Department of Dermatology, University Hospital Münster, Münster, Germany; ⁴Medical Dermatology Specialists, Inc., Atlanta, Georgia, USA; ⁵Department of Medicine, Karolinska Institutet, Solna, Sweden; ⁶University Hospital Bonn, University of Bonn, Bonn, Germany; ⁷UCB Pharma, Raleigh, North Carolina, USA; ⁸UCB Pharma, Monheim, Germany; ⁹Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
References: ¹Korman H et al. Dermatology. 2021;237:151-157. ²Gorelick J et al. Dermatol Ther (Heidelb). 2019;9:785-797. ³Takekoshi J et al. J Am Acad Dermatol. 2017;76:377-390. ⁴Blauvelt A et al. J Drugs Dermatol. 2020;19:487-492. ⁵Warren RB et al. N Engl J Med. 2021;385:130-141. ⁶NCT03412747. ⁷Reich K et al. N Engl J Med. 2021;385:142-152. ⁸NCT03536884. ⁹Gordon KB et al. Lancet. 2021;397:475-486. ¹⁰NCT03410992. **Author Contributions:** Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: AB, KCD, NM, JW, MS, DWT, MW, KW, BS, LP. Drafting of the publication, or revising it critically for important intellectual content: AB, KCD, NM, JW, MS, DWT, MW, KW, BS, LP. Final approval of the publication: AB, KCD, NM, JW, MS, DWT, MW, KW, BS, LP. **Author Disclosures:** AB: Has served as a speaker (received honoraria) for AbbVie, Arcutis, Bristol Myers Squibb, Eli Lilly, Pfizer, Regeneron, Sanofi, and UCB Pharma, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Bluebird bio, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, EcoR1, Eli Lilly, Escent, Eveto, Evonimmune, Forté, Galderma, Highlight PH, Inocyte, InovventBio, Janssen, Landos, LEO Pharma, Merck, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, Trialspark, UCB Pharma, Vibromo, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, Eli Lilly, Evelo, Evonimmune, Galderma, Inocyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and UCB Pharma. **KCD:** Received grants/investigator for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Sierra, Stiefel, and UCB Pharma; speaker's bureau for Novartis (non-promotional only); consultant/advisory board for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Ortho Dermatologics, Pfizer, Sierra, Stiefel, and UCB Pharma. **NM:** Honoraria for participation on advisory boards, as a speaker and for consultancy from AbbVie, Almirall, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, and UCB Pharma. **JW:** Research grants from AbbVie, Amgen, Avillion, Boehringer Ingelheim, Bristol Myers Squibb, ChemoCentryx, Dermira, GSK, Inlira, LEO Pharma, Janssen, Novartis, Regeneron, Sanofi, and UCB Pharma; consulting fees from AbbVie, Janssen, Novartis, Regeneron, Sanofi, and UCB Pharma; speaker's bureau from AbbVie, Janssen, Novartis, Regeneron, and Sanofi. **MS:** Has received honoraria for participating in advisory boards and has given lectures for AbbVie, Celgene, Eli Lilly, LEO Pharma, Lipitor, Novartis, Pfizer, and UCB Pharma. **DWT:** Has been an advisor and/or received speakers' honoraria or travel expense reimbursements and/or participated in trials sponsored by AbbVie, Almirall, Amgen, Beiersdorf, Biogen, Boehringer Ingelheim, Celgene, Forward Pharma, GSK, Janssen, LEO Pharma, Eli Lilly, Medac, Merck, Novartis, Pfizer, UCB Pharma, and VBI. **MW, KW, BS:** Employees and shareholders of UCB Pharma. **LP:** Received consultant/speaker's honoraria from and/or participated in trials sponsored by AbbVie, Almirall, Amgen, Bavaria, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly, Gebro, Janssen, JSCAD, LEO Pharma, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Samsung-Bioepis, Sandoz, Sanofi Genzyme, and UCB Pharma. **Acknowledgements:** This study was funded by UCB Pharma. We thank the patients and their caregivers in addition to the investigators and their teams who contributed to this study. The authors acknowledge Susanne Wiegatz, MSc, UCB Pharma, Monheim, Germany, for publication coordination, Natalia Nunez Gomez, MD, UCB Pharma, Monheim, Germany, for critical review, Yasha Najafi, MSc, Costello Medical, London, UK, for medical writing and editorial assistance and the Design team, Costello Medical, UK for graphic design assistance. All costs associated with development of this poster were funded by UCB Pharma.

Previously presented at SPIN 2022

Conclusions

At Week 4, after one dose of BKZ, greater levels of skin clearance and HRQoL benefits were observed compared with two doses of ADA, one dose of UST, and four doses of SEC.

Results were consistent across the four phase 3/3b trials.